ATE408416T1 - Intrakraniale behandlung neuropsychiatrischer krankheiten mit clostridium neurotoxinen wie botulinus toxin - Google Patents

Intrakraniale behandlung neuropsychiatrischer krankheiten mit clostridium neurotoxinen wie botulinus toxin

Info

Publication number
ATE408416T1
ATE408416T1 AT03718383T AT03718383T ATE408416T1 AT E408416 T1 ATE408416 T1 AT E408416T1 AT 03718383 T AT03718383 T AT 03718383T AT 03718383 T AT03718383 T AT 03718383T AT E408416 T1 ATE408416 T1 AT E408416T1
Authority
AT
Austria
Prior art keywords
neuropsychiatric diseases
botulinus toxin
intracranial treatment
clostridium neurotoxins
neurotoxins
Prior art date
Application number
AT03718383T
Other languages
English (en)
Inventor
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE408416T1 publication Critical patent/ATE408416T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03718383T 2002-05-10 2003-04-11 Intrakraniale behandlung neuropsychiatrischer krankheiten mit clostridium neurotoxinen wie botulinus toxin ATE408416T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/143,078 US6921538B2 (en) 2002-05-10 2002-05-10 Therapeutic treatments for neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
ATE408416T1 true ATE408416T1 (de) 2008-10-15

Family

ID=29400026

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03718383T ATE408416T1 (de) 2002-05-10 2003-04-11 Intrakraniale behandlung neuropsychiatrischer krankheiten mit clostridium neurotoxinen wie botulinus toxin

Country Status (10)

Country Link
US (3) US6921538B2 (de)
EP (1) EP1503790B1 (de)
JP (1) JP4624777B2 (de)
AT (1) ATE408416T1 (de)
AU (1) AU2003221922B8 (de)
BR (1) BR0309888A (de)
CA (1) CA2484774C (de)
DE (1) DE60323628D1 (de)
ES (1) ES2314193T3 (de)
WO (1) WO2003094955A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9042988B2 (en) 1998-08-05 2015-05-26 Cyberonics, Inc. Closed-loop vagus nerve stimulation
US9320900B2 (en) 1998-08-05 2016-04-26 Cyberonics, Inc. Methods and systems for determining subject-specific parameters for a neuromodulation therapy
US8762065B2 (en) 1998-08-05 2014-06-24 Cyberonics, Inc. Closed-loop feedback-driven neuromodulation
US7403820B2 (en) 1998-08-05 2008-07-22 Neurovista Corporation Closed-loop feedback-driven neuromodulation
US9415222B2 (en) 1998-08-05 2016-08-16 Cyberonics, Inc. Monitoring an epilepsy disease state with a supervisory module
US9375573B2 (en) 1998-08-05 2016-06-28 Cyberonics, Inc. Systems and methods for monitoring a patient's neurological disease state
US7242984B2 (en) 1998-08-05 2007-07-10 Neurovista Corporation Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US7277758B2 (en) 1998-08-05 2007-10-02 Neurovista Corporation Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder
US7209787B2 (en) 1998-08-05 2007-04-24 Bioneuronics Corporation Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US7231254B2 (en) 1998-08-05 2007-06-12 Bioneuronics Corporation Closed-loop feedback-driven neuromodulation
US7747325B2 (en) 1998-08-05 2010-06-29 Neurovista Corporation Systems and methods for monitoring a patient's neurological disease state
US7324851B1 (en) 1998-08-05 2008-01-29 Neurovista Corporation Closed-loop feedback-driven neuromodulation
AU1943301A (en) * 1999-12-02 2001-06-12 General Hospital Corporation, The Method and apparatus for measuring indices of brain activity
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
EP1982997B1 (de) 2004-09-01 2012-08-08 Allergan, Inc. Abbaubare Clostridientoxine
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
CA2601592A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
WO2008036060A2 (en) 2005-04-05 2008-03-27 Allergan, Inc. Clostridial toxin activity assays
EP2248534A1 (de) * 2005-06-14 2010-11-10 Botulinum Toxin Research Associates, Inc. Botulinumtoxin und die Behandlung von primären Stimmungs- und Affektivenstörungen
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
JP5826450B2 (ja) 2005-07-22 2015-12-02 ザ ファウンドリー， エルエルシー 治療薬の送達のためのシステムおよび方法
US9511210B2 (en) * 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
US8868172B2 (en) 2005-12-28 2014-10-21 Cyberonics, Inc. Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders
US8725243B2 (en) 2005-12-28 2014-05-13 Cyberonics, Inc. Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
US20080027515A1 (en) 2006-06-23 2008-01-31 Neuro Vista Corporation A Delaware Corporation Minimally Invasive Monitoring Systems
US8295934B2 (en) 2006-11-14 2012-10-23 Neurovista Corporation Systems and methods of reducing artifact in neurological stimulation systems
EP2120684B1 (de) * 2006-12-22 2015-09-09 Washington University Hochleistungsabbildungssystem für eine diffuse optische tomographie und dazugehöriges verwendungsverfahren
US20080183097A1 (en) 2007-01-25 2008-07-31 Leyde Kent W Methods and Systems for Measuring a Subject's Susceptibility to a Seizure
WO2008092119A2 (en) 2007-01-25 2008-07-31 Neurovista Corporation Systems and methods for identifying a contra-ictal condition in a subject
US8036736B2 (en) 2007-03-21 2011-10-11 Neuro Vista Corporation Implantable systems and methods for identifying a contra-ictal condition in a subject
US9788744B2 (en) 2007-07-27 2017-10-17 Cyberonics, Inc. Systems for monitoring brain activity and patient advisory device
US9259591B2 (en) 2007-12-28 2016-02-16 Cyberonics, Inc. Housing for an implantable medical device
US20090171168A1 (en) 2007-12-28 2009-07-02 Leyde Kent W Systems and Method for Recording Clinical Manifestations of a Seizure
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US9480425B2 (en) * 2008-04-17 2016-11-01 Washington University Task-less optical mapping of dynamic brain function using resting state functional connectivity
KR101719824B1 (ko) 2008-05-09 2017-04-04 호라이라 인코포레이티드 기관지나무 치료용 시스템, 어셈블리 및 방법
JPWO2010013495A1 (ja) * 2008-07-31 2012-01-05 一般財団法人化学及血清療法研究所 高度精製ボツリヌス毒素治療剤を有効成分として含有する薬学的組成物およびその利用
US8849390B2 (en) 2008-12-29 2014-09-30 Cyberonics, Inc. Processing for multi-channel signals
US8588933B2 (en) 2009-01-09 2013-11-19 Cyberonics, Inc. Medical lead termination sleeve for implantable medical devices
US8786624B2 (en) 2009-06-02 2014-07-22 Cyberonics, Inc. Processing for multi-channel signals
WO2011041483A2 (en) 2009-09-30 2011-04-07 Toxcure, Inc. Use of botulinum neurotoxin to treat substance addictions
CN107049479B (zh) 2009-10-27 2020-10-16 努瓦拉公司 具有可冷却的能量发射组件的递送装置
CN106618731B (zh) 2009-11-11 2020-08-07 努瓦拉公司 用于处理组织和控制狭窄的系统、装置和方法
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
JP2011157331A (ja) * 2010-02-03 2011-08-18 Chemo-Sero-Therapeutic Research Inst 高用量投与が可能なボツリヌス毒素製剤
US9643019B2 (en) 2010-02-12 2017-05-09 Cyberonics, Inc. Neurological monitoring and alerts
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
US10111938B2 (en) 2011-03-30 2018-10-30 Allergan, Inc. Injection paradigm for administration of botulinum toxins
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
AU2013246882B2 (en) 2012-04-13 2017-10-19 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (II)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
EP2919807B1 (de) 2012-11-16 2018-07-11 Finzi, Eric Behandlung von posttraumatischen stresszuständen mit botulinumtoxin a
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201313356D0 (en) * 2013-07-26 2013-09-11 Ucl Business Plc Therapeutic Intervention
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
PT3242884T (pt) 2015-01-09 2021-04-22 Ipsen Bioinnovation Ltd Neurotoxinas catiónicas
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (de) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Herstellung von aktivierten clostridien-neurotoxinen
EP3519430A1 (de) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybridneurotoxine
US10786010B2 (en) 2017-12-15 2020-09-29 Rai Strategic Holdings, Inc. Aerosol delivery device with multiple aerosol delivery pathways
US20210187194A1 (en) 2018-02-26 2021-06-24 Ipsen Biopharm Limited Use of Ultrasound to Guide Injection of Non-cytotoxic Protease
JP2022500387A (ja) 2018-09-10 2022-01-04 アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム Ｍｕｓｋ阻害
EP4045073A4 (de) 2019-10-18 2022-12-07 Penland Foundation Botulinumtoxin zur verwendung in der behandlung
GB201917265D0 (en) 2019-11-27 2020-01-08 Univ Sheffield Bonded neurotoxins
TWI854077B (zh) 2019-12-20 2024-09-01 瑞士商葛德瑪控股公司 生產肉毒桿菌毒素的方法
MX2022011856A (es) 2020-04-17 2023-02-23 Univ New York Anticuerpos de proteina tirosina cinasa especifica de musculo humano (musk) terapeuticos.
CN113832069B (zh) * 2020-11-30 2024-01-30 河南农业大学 丁酸梭菌及其应用
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
EP4593873A1 (de) 2022-09-30 2025-08-06 Ipsen Biopharm Limited Clostridium-neurotoxin zur verwendung bei der behandlung von blasenschmerzsyndrom
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741902A (en) * 1986-07-14 1988-05-03 Haast William E Compositions for treatment of neurological and related disorders
US5352447A (en) * 1987-10-05 1994-10-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy
DE4004573A1 (de) * 1989-02-17 1990-08-23 Tanabe Seiyaku Co Neues versuchstier und seine herstellung
US5549884A (en) * 1992-10-28 1996-08-27 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Rat or mouse exhibiting behaviors associated with human schizophrenia
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
ES2159624T3 (es) * 1993-12-28 2001-10-16 Allergan Sales Inc Toxinas botulinicas para el tratamiento de la hiperhidrosis.
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
EP1086702B1 (de) * 1994-05-09 2005-04-13 BINDER, William J. Präsynaptische Neurotoxine gegen Migränekopfschmerzen
US6203794B1 (en) * 1994-05-31 2001-03-20 Allergan Sales, Inc. Modification of clostridial toxins for use as transport proteins
SE9401965D0 (sv) * 1994-06-07 1994-06-07 Astra Ab New compounds
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6071493A (en) * 1996-09-20 2000-06-06 Baylor College Of Medicine Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
US6272370B1 (en) * 1998-08-07 2001-08-07 The Regents Of University Of Minnesota MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
WO1999055359A1 (en) * 1998-04-29 1999-11-04 Allergan Sales, Inc. Compositions and methods for extending the action of clostridial neurotoxin
CN1318105A (zh) * 1998-09-15 2001-10-17 M&E生物技术公司 负调节Osteoprotegerin配体活性的方法
ATE314859T1 (de) * 1998-10-27 2006-02-15 Mayo Foundation Botulinumtoxine zur verstärkung der wundheilung
US6545126B1 (en) * 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US7255866B2 (en) * 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
DE10150415A1 (de) 2001-10-11 2003-05-15 Andres O Ceballos-Baumann Arzneimittel zur Prophylaxe und Therapie von Depressionen
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US7897147B2 (en) * 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders

Also Published As

Publication number Publication date
AU2003221922B8 (en) 2009-06-18
DE60323628D1 (de) 2008-10-30
CA2484774A1 (en) 2003-11-20
JP4624777B2 (ja) 2011-02-02
CA2484774C (en) 2012-07-10
US6921538B2 (en) 2005-07-26
BR0309888A (pt) 2005-03-22
JP2005530770A (ja) 2005-10-13
US20070218085A1 (en) 2007-09-20
US20040180061A1 (en) 2004-09-16
AU2003221922B2 (en) 2006-09-28
ES2314193T3 (es) 2009-03-16
EP1503790A1 (de) 2005-02-09
EP1503790B1 (de) 2008-09-17
US7229626B2 (en) 2007-06-12
WO2003094955A1 (en) 2003-11-20
AU2003221922A1 (en) 2003-11-11
US20030211121A1 (en) 2003-11-13
US7811587B2 (en) 2010-10-12

Similar Documents

Publication Publication Date Title
ATE408416T1 (de) Intrakraniale behandlung neuropsychiatrischer krankheiten mit clostridium neurotoxinen wie botulinus toxin
MXPA02009932A (es) Metodo apra el tratamiento del dolor mediante administracion periferica de una neurotoxina.
BR0111698A (pt) Método para o tratamento de um distúrbio de movimento
BR0014710A (pt) Métodos para o tratamento de dor
AR028939A1 (es) Metodo para tratar un desorden pancreatico con una neurotoxina
MXPA03002576A (es) Metodos para tratar lesiones musculares.
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
ATE452652T1 (de) Behandlung neurologischer und neuropsychiatrischer erkrankungen mit botulinumtoxin
TW200503751A (en) Methods for treating sinus headache
BRPI0910993A2 (pt) técnica de administração na linha de sutura usando toxinas botulínicas
BRPI0417493A (pt) terapia com toxina botulìnica para distúrbios da pele
ATE385806T1 (de) Fusionsproteine
BR0312506A (pt) Composições transdérmicas de toxina botulìnica
DK2145629T3 (da) Anvendelse af neurotoksinterapi til behandling af urologiske og relaterede sygdomme
ATE373679T1 (de) Antimikrobiell wirksames oder endotoxin neutralisierendes polypeptid
DE60310400D1 (de) Botulinustoxine zur behandlung von priapismus
RU2012110324A (ru) Способы лечения хронического нейрогенного воспаления с помощью модифицированного клостридиального токсина
DE60306505D1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
HRP20050903A2 (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
DE602005010676D1 (de) Behandlung von druckgeschwüren
MY151447A (en) Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
DE69724818D1 (de) Medizinische Verwendung des scuPA/suPAR Komplexes
WO2009021926A3 (de) Verwendung eines neurotoxins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee